World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Economics and Finance 50 1387 1235 842 731 261 8987

Louis P. Garrison publications per year

The chart shows the history of publications by Louis P. Garrison between 1981 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Louis P. Garrison published across 45 years, from 1981 to 2025, averaging 8 papers a year. Output peaked at 27 publications in 2011. 32 of the 362 publications appeared in the last two years.

No. of publications
5 10 15 20 25
Bar chart. Horizontal axis: year, 1981 to 2025. Vertical axis: number of publications, 0 to 27. Peak 27 publications in 2011. 1981: 1 publication 1982: 0 publications 1983: 1 publication 1984: 3 publications 1985: 1 publication 1986: 2 publications 1987: 0 publications 1988: 0 publications 1989: 0 publications 1990: 0 publications 1991: 0 publications 1992: 0 publications 1993: 1 publication 1994: 0 publications 1995: 0 publications 1996: 1 publication 1997: 3 publications 1998: 1 publication 1999: 0 publications 2000: 0 publications 2001: 1 publication 2002: 1 publication 2003: 3 publications 2004: 1 publication 2005: 1 publication 2006: 8 publications 2007: 10 publications 2008: 10 publications 2009: 15 publications 2010: 23 publications 2011: 27 publications 2012: 21 publications 2013: 22 publications 2014: 18 publications 2015: 14 publications 2016: 21 publications 2017: 22 publications 2018: 18 publications 2019: 22 publications 2020: 11 publications 2021: 18 publications 2022: 15 publications 2023: 14 publications 2024: 21 publications 2025: 11 publications
1981 2025

362 publications in total across all disciplines

View publications per year as a table
Louis P. Garrison: publications per year, 1981 to 2025
Year Publications
1981 1
1982 0
1983 1
1984 3
1985 1
1986 2
1987 0
1988 0
1989 0
1990 0
1991 0
1992 0
1993 1
1994 0
1995 0
1996 1
1997 3
1998 1
1999 0
2000 0
2001 1
2002 1
2003 3
2004 1
2005 1
2006 8
2007 10
2008 10
2009 15
2010 23
2011 27
2012 21
2013 22
2014 18
2015 14
2016 21
2017 22
2018 18
2019 22
2020 11
2021 18
2022 15
2023 14
2024 21
2025 11
Total 362
Download as CSV

Louis P. Garrison publication distribution in Economics and Finance in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Economics and Finance in 2026. The highlighted bar marks where Louis P. Garrison sits on this spectrum.

No. of scientists
25 50 75 100
Bar chart with 97 bars. Horizontal axis: publications, 42–46 to 521+. Vertical axis: number of scientists, 0 to 111. Most scientists, 111, have 137–141 publications. The last bar groups every scientist with 521 publications or more. The highlighted bar, 257–261 publications, is where this scientist sits. 42–46 publications: 1 scientist 47–51 publications: 12 scientists 52–56 publications: 7 scientists 57–61 publications: 23 scientists 62–66 publications: 32 scientists 67–71 publications: 36 scientists 72–76 publications: 56 scientists 77–81 publications: 57 scientists 82–86 publications: 70 scientists 87–91 publications: 86 scientists 92–96 publications: 72 scientists 97–101 publications: 106 scientists 102–106 publications: 97 scientists 107–111 publications: 96 scientists 112–116 publications: 101 scientists 117–121 publications: 103 scientists 122–126 publications: 102 scientists 127–131 publications: 108 scientists 132–136 publications: 107 scientists 137–141 publications: 111 scientists 142–146 publications: 94 scientists 147–151 publications: 96 scientists 152–156 publications: 100 scientists 157–161 publications: 74 scientists 162–166 publications: 68 scientists 167–171 publications: 91 scientists 172–176 publications: 76 scientists 177–181 publications: 75 scientists 182–186 publications: 61 scientists 187–191 publications: 66 scientists 192–196 publications: 68 scientists 197–201 publications: 71 scientists 202–206 publications: 60 scientists 207–211 publications: 56 scientists 212–216 publications: 44 scientists 217–221 publications: 51 scientists 222–226 publications: 65 scientists 227–231 publications: 48 scientists 232–236 publications: 59 scientists 237–241 publications: 37 scientists 242–246 publications: 37 scientists 247–251 publications: 41 scientists 252–256 publications: 43 scientists 257–261 publications: 33 scientists 262–266 publications: 34 scientists 267–271 publications: 39 scientists 272–276 publications: 25 scientists 277–281 publications: 29 scientists 282–286 publications: 29 scientists 287–291 publications: 26 scientists 292–296 publications: 31 scientists 297–301 publications: 31 scientists 302–306 publications: 24 scientists 307–311 publications: 28 scientists 312–316 publications: 24 scientists 317–321 publications: 13 scientists 322–326 publications: 14 scientists 327–331 publications: 25 scientists 332–336 publications: 18 scientists 337–341 publications: 16 scientists 342–346 publications: 18 scientists 347–351 publications: 15 scientists 352–356 publications: 17 scientists 357–361 publications: 19 scientists 362–366 publications: 16 scientists 367–371 publications: 17 scientists 372–376 publications: 7 scientists 377–381 publications: 18 scientists 382–386 publications: 13 scientists 387–391 publications: 19 scientists 392–396 publications: 9 scientists 397–401 publications: 10 scientists 402–406 publications: 13 scientists 407–411 publications: 13 scientists 412–416 publications: 5 scientists 417–421 publications: 10 scientists 422–426 publications: 6 scientists 427–431 publications: 12 scientists 432–436 publications: 9 scientists 437–441 publications: 9 scientists 442–446 publications: 10 scientists 447–451 publications: 12 scientists 452–456 publications: 8 scientists 457–461 publications: 4 scientists 462–466 publications: 7 scientists 467–471 publications: 4 scientists 472–476 publications: 5 scientists 477–481 publications: 6 scientists 482–486 publications: 7 scientists 487–491 publications: 8 scientists 492–496 publications: 5 scientists 497–501 publications: 4 scientists 502–506 publications: 4 scientists 507–511 publications: 5 scientists 512–516 publications: 7 scientists 517–520 publications: 7 scientists 521+ publications: 99 scientists
42–46 publications 521+

This scientist: 261 publications — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 521 publications or more.

View publications distribution as a table
Number of Economics and Finance scientists by publication count, Research.com 2026 ranking edition. Based on 3,760 ranked scientists.
Publications Scientists This scientist
42–46 1
47–51 12
52–56 7
57–61 23
62–66 32
67–71 36
72–76 56
77–81 57
82–86 70
87–91 86
92–96 72
97–101 106
102–106 97
107–111 96
112–116 101
117–121 103
122–126 102
127–131 108
132–136 107
137–141 111
142–146 94
147–151 96
152–156 100
157–161 74
162–166 68
167–171 91
172–176 76
177–181 75
182–186 61
187–191 66
192–196 68
197–201 71
202–206 60
207–211 56
212–216 44
217–221 51
222–226 65
227–231 48
232–236 59
237–241 37
242–246 37
247–251 41
252–256 43
257–261 33 261
262–266 34
267–271 39
272–276 25
277–281 29
282–286 29
287–291 26
292–296 31
297–301 31
302–306 24
307–311 28
312–316 24
317–321 13
322–326 14
327–331 25
332–336 18
337–341 16
342–346 18
347–351 15
352–356 17
357–361 19
362–366 16
367–371 17
372–376 7
377–381 18
382–386 13
387–391 19
392–396 9
397–401 10
402–406 13
407–411 13
412–416 5
417–421 10
422–426 6
427–431 12
432–436 9
437–441 9
442–446 10
447–451 12
452–456 8
457–461 4
462–466 7
467–471 4
472–476 5
477–481 6
482–486 7
487–491 8
492–496 5
497–501 4
502–506 4
507–511 5
512–516 7
517–520 7
521+ 99
Download as CSV

Louis P. Garrison D-index placement in Economics and Finance in 2026

The chart shows the D-index (discipline H-index) distribution of Economics and Finance scientists ranked by Research.com in 2026. The highlighted bar marks where Louis P. Garrison sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 72 bars. Horizontal axis: D-Index, 30 to 101+. Vertical axis: number of scientists, 0 to 178. Most scientists, 178, have 33 D-Index. The last bar groups every scientist with 101 D-Index or more. The highlighted bar, 50 D-Index, is where this scientist sits. 30 D-Index: 126 scientists 31 D-Index: 147 scientists 32 D-Index: 157 scientists 33 D-Index: 178 scientists 34 D-Index: 171 scientists 35 D-Index: 141 scientists 36 D-Index: 132 scientists 37 D-Index: 129 scientists 38 D-Index: 130 scientists 39 D-Index: 120 scientists 40 D-Index: 117 scientists 41 D-Index: 113 scientists 42 D-Index: 114 scientists 43 D-Index: 97 scientists 44 D-Index: 115 scientists 45 D-Index: 86 scientists 46 D-Index: 78 scientists 47 D-Index: 83 scientists 48 D-Index: 62 scientists 49 D-Index: 74 scientists 50 D-Index: 50 scientists 51 D-Index: 66 scientists 52 D-Index: 69 scientists 53 D-Index: 55 scientists 54 D-Index: 67 scientists 55 D-Index: 61 scientists 56 D-Index: 62 scientists 57 D-Index: 45 scientists 58 D-Index: 34 scientists 59 D-Index: 47 scientists 60 D-Index: 46 scientists 61 D-Index: 36 scientists 62 D-Index: 37 scientists 63 D-Index: 56 scientists 64 D-Index: 50 scientists 65 D-Index: 32 scientists 66 D-Index: 28 scientists 67 D-Index: 30 scientists 68 D-Index: 24 scientists 69 D-Index: 25 scientists 70 D-Index: 22 scientists 71 D-Index: 21 scientists 72 D-Index: 26 scientists 73 D-Index: 24 scientists 74 D-Index: 23 scientists 75 D-Index: 12 scientists 76 D-Index: 14 scientists 77 D-Index: 15 scientists 78 D-Index: 15 scientists 79 D-Index: 17 scientists 80 D-Index: 17 scientists 81 D-Index: 11 scientists 82 D-Index: 10 scientists 83 D-Index: 16 scientists 84 D-Index: 11 scientists 85 D-Index: 5 scientists 86 D-Index: 9 scientists 87 D-Index: 13 scientists 88 D-Index: 9 scientists 89 D-Index: 7 scientists 90 D-Index: 6 scientists 91 D-Index: 4 scientists 92 D-Index: 8 scientists 93 D-Index: 10 scientists 94 D-Index: 11 scientists 95 D-Index: 6 scientists 96 D-Index: 4 scientists 97 D-Index: 4 scientists 98 D-Index: 6 scientists 99 D-Index: 6 scientists 100 D-Index: 8 scientists 101+ D-Index: 100 scientists
30 D-Index 101+

This scientist: 50 D-Index — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 101 D-Index or more.

View D-Index distribution as a table
Number of Economics and Finance scientists by D-index, Research.com 2026 ranking edition. Based on 3,760 ranked scientists.
D-Index Scientists This scientist
30 126
31 147
32 157
33 178
34 171
35 141
36 132
37 129
38 130
39 120
40 117
41 113
42 114
43 97
44 115
45 86
46 78
47 83
48 62
49 74
50 50 50
51 66
52 69
53 55
54 67
55 61
56 62
57 45
58 34
59 47
60 46
61 36
62 37
63 56
64 50
65 32
66 28
67 30
68 24
69 25
70 22
71 21
72 26
73 24
74 23
75 12
76 14
77 15
78 15
79 17
80 17
81 11
82 10
83 16
84 11
85 5
86 9
87 13
88 9
89 7
90 6
91 4
92 8
93 10
94 11
95 6
96 4
97 4
98 6
99 6
100 8
101+ 100
Download as CSV

Overview

Louis P. Garrison is affiliated with the University of Washington in the United States. Their research spans multiple areas focused primarily on economics, health systems, and pharmaceutical policy. The main fields of study associated with their work include Economics, Econometrics and Finance as well as Medicine, with a significant contribution to Economics and Econometrics and General Health Professions as notable subfields.

The scientist has explored diverse topics, including:

  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmaceutical Economics and Policy
  • Healthcare cost, quality, practices
  • Economic and Financial Impacts of Cancer
  • Biosimilars and Bioanalytical Methods
  • Hemophilia Treatment and Research
  • Innovation Policy and R&D

Frequent coauthors with whom they have collaborated include:

  • William B. Wong
  • Meng Li
  • David L. Veenstra
  • Boshen Jiao
  • Stacey Kowal

Louis P. Garrison's publications often appear in respected venues such as:

  • Value in Health
  • Journal of Managed Care & Specialty Pharmacy
  • PharmacoEconomics
  • Journal of Medical Economics
  • Journal of Clinical Oncology

Some of their recent papers include:

  • "Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations," 2020, published in Pain
  • "The History and Future of the 'ISPOR Value Flower': Addressing Limitations of Conventional Cost-Effectiveness Analysis," 2022, published in Value in Health
  • "HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies," 2020, published in The European Journal of Health Economics
  • "Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A," 2020, published in Journal of Medical Economics
  • "Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective," 2020, published in Journal for ImmunoTherapy of Cancer

Best Publications

  • Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

    Louis P. Garrison;Peter J. Neumann;Pennifer Erickson;Deborah Marshall

  • Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].

    Darius N. Lakdawalla;Jalpa A. Doshi;Louis P. Garrison;Charles E. Phelps

  • Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.

    Josh J. Carlson;Sean D. Sullivan;Louis P. Garrison;Peter J. Neumann

  • Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.

    Louis P. Garrison;Adrian Towse;Andrew Briggs;Gerard de Pouvourville

  • An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].

    Louis P. Garrison;Mark V. Pauly;Richard J. Willke;Peter J. Neumann

  • Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.

    Eric Faulkner;Lieven Annemans;Lou Garrison;Mark Helfand

  • Good research practices for measuring drug costs in cost-effectiveness analyses

    Louis P. Garrison;Edward C. Mansley;Thomas A. Abbott;Brian W. Bresnahan

  • Economic Evaluation of Influenza Pandemic Mitigation Strategies in the United States Using a Stochastic Microsimulation Transmission Model

    Beate Sander;Azhar Nizam;Louis P. Garrison;Maarten J. Postma

  • A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]

    Louis P. Garrison;Peter J. Neumann;Richard J. Willke;Anirban Basu

  • Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.

    Adrian Towse;Louis P. Garrison

  • Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.

    Cassidy J;Douillard Jy;Twelves C;McKendrick Jj

  • Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer

    Louis P. Garrison;Deborah Lubeck;Deepa Lalla;Virginia Paton

  • A Health Economics Approach to US Value Assessment Frameworks—Introduction: An ISPOR Special Task Force Report [1]

    Peter J. Neumann;Richard J. Willke;Louis P. Garrison

  • Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations.

    Shannon M Smith;Robert H Dworkin;Dennis C Turk;Michael McDermott

  • Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis

    Louis P. Garrison;Sachin Kamal-Bahl;Adrian Towse

  • Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I

    Joel W. Hay;Jim Smeeding;Norman V. Carroll;Michael Drummond

  • Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report

    Josephine Mauskopf;Baudouin Standaert;Mark P. Connolly;Anthony J. Culyer

  • Interspecialty variation in office-based care.

    Greenwald Hp;Peterson Ml;Garrison Lp;Hart Lg

  • Assessing A Structured, Quantitative Health Outcomes Approach To Drug Risk-Benefit Analysis

    Louis P. Garrison;Adrian Towse;Brian W. Bresnahan

  • A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice.

    David L Veenstra;Joshua A Roth;Louis P Garrison;Scott D Ramsey;Scott D Ramsey

  • Global Eradication of Measles: An Epidemiologic and Economic Evaluation

    Ann Levin;Colleen Burgess;Louis P. Garrison;Chris Bauch

  • Linking pharmacogenetics-based diagnostics and drugs for personalized medicine.

    Louis P. Garrison;M.J. Finley Austin

Frequent Co-Authors

Adrian Towse
Adrian Towse Office Of Health Economics
Sean D. Sullivan
Sean D. Sullivan University of Washington
Scott D. Ramsey
Scott D. Ramsey Fred Hutchinson Cancer Research Center
Peter J. Neumann
Peter J. Neumann University of Bern
David R. Flum
David R. Flum University of Washington
Anirban Basu
Anirban Basu University of Washington
James G. Kublin
James G. Kublin Fred Hutchinson Cancer Research Center
Philippe Généreux
Philippe Généreux Morristown Medical Center
Andrew Briggs
Andrew Briggs University of Glasgow
Edith A. Perez
Edith A. Perez Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Economics and Finance opens the door to many educational pathways tailored to evolving industry needs. For those seeking rapid advancement, 1 year mba programs in usa provide an intensive curriculum that prepares graduates for leadership roles in a short timeframe.

If your interests include building and managing new ventures, pursuing an online mba entrepreneurship degree can equip you with practical skills for launching startups or innovating within existing organizations. Affordability and flexibility are key benefits of this study mode.

Project management is another growing area in business. Understanding what is a project management degree can help you determine how these credentials lead to roles in planning, executing, and overseeing complex projects across various industries.

Finally, for those looking to balance budget and quality, the cheapest online finance degree options offer a fast and cost-effective way to gain credentials that are increasingly sought after in banking, investment, and corporate finance sectors.

Best Scientists Citing Louis P. Garrison

Trending Scientists

Recently Published Articles